Infliximab shows superior drug survival among biologics for hidradenitis suppurativa: A cohort study

Albert T Young; Kathy Lu; Andrea Dai; Iltefat Hamzavi; Richard H Huggins; Indra Adrianto; Li Zhou; Qing-Sheng Mi

doi:10.1016/j.jaad.2024.06.110

Infliximab shows superior drug survival among biologics for hidradenitis suppurativa: A cohort study

J Am Acad Dermatol. 2024 Sep 17:S0190-9622(24)02828-7. doi: 10.1016/j.jaad.2024.06.110. Online ahead of print.

Authors

Albert T Young¹, Kathy Lu¹, Andrea Dai¹, Iltefat Hamzavi¹, Richard H Huggins¹, Indra Adrianto², Li Zhou³, Qing-Sheng Mi⁴

Affiliations

¹ Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Detroit, Michigan.
² Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan.
³ Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Internal Medicine, Henry Ford Health, Detroit, Michigan.
⁴ Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Detroit, Michigan; Center for Bioinformatics, Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan; Henry Ford Health + Michigan State University Health Sciences, East Lansing, Michigan; Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health, Detroit, Michigan; Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan; Department of Internal Medicine, Henry Ford Health, Detroit, Michigan. Electronic address: qmi1@hfhs.org.

PMID: 39299517
DOI: 10.1016/j.jaad.2024.06.110

No abstract available

Keywords: TNF-α inhibitors; adalimumab; biologics; drug survival; guselkumab; hidradenitis suppurativa; infliximab; medical dermatology; secukinumab; ustekinumab.